Adc therapeutics sa private company information – bloomberg cancer and white blood cell count

ADC Therapeutics announced preclinical data for its two new investigational programs ADCT-601 targeting AXL and ADCT-701 targeting DLK-1. ADCT-701, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors. ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK1, site-specifically conjugated using GlycoConnectTM technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. ADCT-701 demonstrated potent and specific in vitro and in vivo anti-tumor activity in DLK1-expressing cancer-derived models and it was stable and well tolerated in rats. Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors.


ADCT-601 is an ADC composed of a humanized IgG1 antibody against human AXL, site-specifically conjugated using GlycoConnectTM technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in various cancer-derived models with different levels of membranous AXL, and it was stable and well tolerated in rats. CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies. Novel data identifies CD25 as a previously unrecognized feedback regulator of oncogenic B/TCR-signaling supporting CD25 as a therapeutic target in refractory lymphoid malignancies. ADCT-301 demonstrated durable remissions in patient-derived Ph+ ALL cells PDX models.

ADC Therapeutics announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59thAmerican Society of Hematology (ASH) Annual Meeting in Atlanta, USA. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. Data were presented from 138 evaluable, heavily pre-treated, patients who had failed, or were intolerant to, any established therapy known to provide clinical benefit. The median age of patients was 64 years, and they had a median of 3 prior therapies. Data were reported from Part 1 and Part 2 of the Phase I study as of November 1, 2017. In Part 1 (dose escalation), 88 patients were treated at dose ranges from 15-200 µg/kg. In Part 2 (dose expansion), 50 patients were treated in two cohorts at either 120 or 150 µg/kg. Key findings presented at an oral presentation included: For the 68 response-evaluable patients in Part 1 at doses greater than or equal to 120 µg/kg, the ORR was 60% (41/68) with 24 patients achieving a complete response (35%) and 17 patients achieving a partial response (25%). For the 49 response-evaluable patients in Part 1 with Diffuse Large B-Cell Lymphoma at doses greater than or equal to 120 µg/kg the ORR was 55% (27/49) with 18 patients achieving a complete response (37%) and 9 patients achieving a partial response (18%). ADCT-402 has been reasonably well tolerated. The most common treatment-emergent adverse events of any grade occurring in at least 20% of patients in Part 1 and Part 2 were fatigue (44%), nausea (28%), elevated gamma-glutamyltransferase (27%), anemia (25%), and peripheral edema (25%). The most common Grade 3 or 4 adverse events occurring in at least 5% of patients, regardless of attribution, were reduced neutrophil count (15%), elevated gamma-glutamyltransferase (15%), anemia (12%), reduced platelet count (12%), neutropenia (12%), thrombocytopenia (9%), elevated blood alkaline phosphatase (5%), fatigue (5%), reduced lymphocyte count (5%), and reduced white blood cell count (5%). Dose expansion in Part 2 of the Phase I study may continue using the recommended doses from Part 1 (i.e. 120 or 150 µg/kg). Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Data were presented from 29 evaluable, heavily pre-treated, patients who had failed, or were intolerant to, any established therapy known to provide clinical benefit. The median age of patients was 50 years, and they had a median of 2 prior therapies. Data were reported from Part 1 of the Phase I study as of November 1, 2017. In Part 1 (dose escalation), patients were treated at dose ranges from 15-150 µg/kg every three weeks, or at a dose of 50 µg/kg once weekly. Key findings presented at a poster session included: Four patients achieved a complete bone marrow response. ADCT-402 has been reasonably well tolerated. The most common treatment-emergent adverse events of any grade occurring in at least 20% of patients were nausea (31%), fatigue (24%), febrile neutropenia (24%) and headache (24%). The most common Grade 3 or 4 adverse events occurring in at least 10% of patients, regardless of attribution, were febrile neutropenia (24%), reduced neutrophil count (14%), bacteremia (10%), abdominal pain (10%), lung infection (10%) and sepsis (10%). Dose escalation will continue using weekly dosing.